相关实验视频
Updated: Jul 15, 2025

12:08
Improving IV Insulin Administration in a Community Hospital
Published on: June 11, 2012
18.9K
精确的妊娠糖尿病治疗:系统性审查和元分析
Jamie L Benham1, Véronique Gingras2,3, Niamh-Maire McLennan4,5
1Department of Medicine and Community Health Sciences, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada.
Communications medicine
|October 4, 2023
概括
精准医学可以通过识别需要更早服用药物的女性来改善妊娠期糖尿病 (GDM) 治疗. 诊断时的常规临床测量可以预测有效的干预措施,优化对母亲和婴儿的护理.
科学领域:
- 生殖内分泌学 生殖内分泌学
- 代谢障碍 代谢障碍 代谢障碍
- 精准医学是一门精准的医学.
背景情况:
- 孕期糖尿病 (GDM) 影响全球7个怀孕中的1个,对母亲和婴儿构成风险.
- 标准化的GDM治疗未能解决个体患者的异质性.
- 精准医学为风险分层的患者提供了潜在的解决方案,并优化了GDM管理.
研究的目的:
- 确定GDM中有效的生活方式和药理干预的精确标记.
- 探索精准医学方法对GDM风险分层的有用性.
主要方法:
- 进行了两次系统审查,以确定GDM干预措施的预测标记.
- 专注于从常规临床测量中识别标记物,并探索潜在的复杂数据源.
主要成果:
- 对于GDM的精确生活方式干预存在有限的研究.
- 常规的临床测量,如先前的GDM病史,BMI和初始血糖水平,可以预测药物治疗升级的必要性.
- 甲胺,硫尿素和胰岛素是潜在的药理干预措施.
结论:
- 在GDM诊断时的临床测量显示出作为精度标记物的前景.
- 需要进一步的研究,从复杂的数据中识别敏感标记物 (例如,omics) 并评估它们的临床可行性.
- 未来的研究应该调查个性化GDM治疗的先进标记.
相关概念视频
Diabetes Mellitus: Type 2 and Gestational
2.5K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
2.5K
Pathophysiology of Diabetes
959
Diabetes mellitus is a chronic metabolic disorder characterized by hyperglycemia. The four categories of diabetes are type 1 diabetes, type 2 diabetes, other specific types of diabetes, and gestational diabetes.
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...
959
Diabetes: Management and Pharmacotherapy
292
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
292
Diabetes Mellitus: Overview and Type I Subtype
2.7K
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
2.7K
Oral Hypoglycemic Agents: Biguanides and Glitazones
215
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
215
Dipeptidyl Peptidase 4 Inhibitors
196
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
196

